SCHEMBL8019372

SCHEMBL8019372

C=C(C(=O)OC)N(Cc1ccccc1NC(=O)COC)S(=O)(=O)c1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PTGES O14684 3/20 0.41
DAGLA Q9Y4D2 1/20 0.41
KCNH2 Q12809 1/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39
GRK2 P25098 1/20 0.39
PPARG P37231 1/20 0.39
KMT2A Q03164 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
PGR P06401 2/20 0.39
NR3C1 P04150 1/20 0.38
TP53 P04637 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6608669 0.90 KMT2A (0.48) RAB9APTGESMAPTPOLBGRK2
SCHEMBL7390326 0.88 PTGES (0.43) PTGESDAGLAKCNH2MAPTLMNA
SCHEMBL8029945 0.84 MAPT (0.45) PTGESKCNH2MAPTLMNAHPGD
SCHEMBL6610937 0.82 POLB (0.48) PTGESMAPTLMNAPOLBGRK2
SCHEMBL6614500 0.82 KMT2A (0.52) NPC1RAB9AMAPTLMNAHPGD
SCHEMBL5656058 0.79 POLB (0.48) PTGESMAPTPOLBGRK2PPARG
SCHEMBL6611061 0.79 MAPT (0.43) NPC1RAB9AMAPTLMNAPOLB
SCHEMBL6610598 0.78 FLT1 (0.52) KCNH2MAPTLMNAHPGDTP53
SCHEMBL6609835 0.78 POLB (0.48) PTGESMAPTLMNAPOLBGRK2
SCHEMBL6610841 0.78 KEAP1 (0.48) PTGESHPGDL3MBTL1POLBGRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed